The charts of Cytokinetics (CYTK) have caught my attention. Let's take a look at this late-stage bio-pharmaceutical company that is focused on muscle activators and inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining.
More from Investing
But much of what we have is just routine volatility and not a major shift in market action.
New technology could take out some of the pain -- and subjectivity -- for those looking to invest in this emerging line of treatments.
PH looks ready to rally again, according to the charts and indicators.
Subscribers are interested in what to do now, so let's go back to the charts.